Biocon Biologics announced that Express Scripts, a leading pharmacy benefit management organisation in the US, will list Biocon Biologics interchangeable biosimilar Insulin Glargine (Semglee), which will be commercialised by Viatris, as a preferred glargine brand on its National Preferred Formulary (NPF), which includes more than 28 million lives.

Biocon Biologics co-developed Semglee with Viatris and together they are committed to improving patients’ access to sustainable, high-quality and affordable biosimilars.

Commenting on this development, Dr Arun Chandavarkar, Managing Director, Biocon Biologics said “The inclusion of our interchangeable biosimilar insulin glargine in Express Scripts’ National Preferred Formulary (NPF) in the U.S. is a major milestone for Biocon Biologics.  It furthers our mission of enabling affordable access to quality insulins to a large number of patients. We expect our partner to commercialize the product in the U.S. by end of the year and formulary coverage to begin in Jan 2022, making it an important growth driver for Biocon Biologics.”

He further added, ``In July 2021, the U.S. Food and Drug Administration (FDA) had approved our biosimilar Insulin Glargine-yfgn injection (Semglee) as the first interchangeable biosimilar product under the 351(k) regulatory pathway, endorsing our scientific excellence and robust quality comparability data.